当前位置:首页 - 行情中心 - 多瑞医药(301075) - 财务分析 - 现金流量表

多瑞医药

(301075)

  

流通市值:35.75亿  总市值:50.54亿
流通股本:5660.00万   总股本:8000.00万

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金121,044,931.6543,172,346.3186,567,606.94171,654,185.42
  收到的税费返还96,605.48---
  收到其他与经营活动有关的现金6,116,175.92433,912.7810,915,666.37260,085.65
  经营活动现金流入小计127,257,713.0543,606,259.08197,483,273.31171,914,271.07
  购买商品、接受劳务支付的现金113,920,424.5148,492,059.79104,915,236.1107,668,991.25
  支付给职工以及为职工支付的现金35,505,529.9919,780,310.473,107,715.4148,502,565.04
  支付的各项税费5,216,193.75693,111.338,823,054.458,162,520.68
  支付其他与经营活动有关的现金17,049,518.8911,293,284.9656,469,695.9442,306,223.57
  经营活动现金流出小计171,691,667.1480,258,766.48243,315,701.9206,640,300.54
  经营活动产生的现金流量净额-44,433,954.09-36,652,507.4-45,832,428.59-34,726,029.47
二、投资活动产生的现金流量:
  收回投资收到的现金27,000,00025,000,000921,983,0001,035,592,216.8
  取得投资收益收到的现金344,536.4144,480.473,277,925.676,285,947.27
  处置固定资产、无形资产和其他长期资产收回的现金净额560,000408,817.6775,996.59-
  处置子公司及其他营业单位收到的现金净额28,150,594.72-8,800,000-
  收到的其他与投资活动有关的现金42,420,834.48-252,899,763.1924,434,549.84
  投资活动现金流入小计98,475,965.625,553,298.071,187,736,685.451,066,312,713.91
  购建固定资产、无形资产和其他长期资产支付的现金63,896,424.7942,696,360.19101,816,834.9958,381,896.75
  投资支付的现金5,000,0005,000,000812,987,000981,000,000
  取得子公司及其他营业单位支付的现金---15,152,526.84
  支付其他与投资活动有关的现金--100,348,060.525,101,821.01
  投资活动现金流出小计68,896,424.7947,696,360.191,015,151,895.491,079,636,244.6
  投资活动产生的现金流量净额29,579,540.81-22,143,062.12172,584,789.96-13,323,530.69
三、筹资活动产生的现金流量:
  吸收投资收到的现金---2,190,500
  取得借款收到的现金--127,700,000117,700,000
  收到其他与筹资活动有关的现金76,403,810.3256,442,970.07180,0008,082,326
  筹资活动现金流入小计76,403,810.3256,442,970.07127,880,000127,972,826
  偿还债务支付的现金77,700,00016,000,000183,909,09681,400,000
  分配股利、利润或偿付利息支付的现金2,641,826.41,481,267.238,789,100.157,051,001.95
  支付其他与筹资活动有关的现金1,562,686.3-86,774,994.34165,000
  筹资活动现金流出小计81,904,512.717,481,267.23279,473,190.4988,616,001.95
  筹资活动产生的现金流量净额-5,500,702.3838,961,702.84-151,593,190.4939,356,824.05
四、汇率变动对现金及现金等价物的影响---1,462.29-
五、现金及现金等价物净增加额-20,355,115.66-19,833,866.68-24,842,291.41-8,692,736.11
  加:期初现金及现金等价物余额85,276,030.585,278,030.5110,118,321.91262,128,315.39
  期末现金及现金等价物余额64,920,914.8465,444,163.8285,276,030.5253,435,579.28
补充资料:
  净利润3,240,666.51--132,401,390.23-
  资产减值准备-2,143,241.49-5,992,360.28-
  固定资产和投资性房地产折旧23,796,357.06-46,959,981.83-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧23,796,357.06-46,959,981.83-
  无形资产摊销1,467,408-2,194,957.39-
  长期待摊费用摊销139,991.3-318,955.98-
  处置固定资产、无形资产和其他长期资产的损失-242,762.47-105,451.29-
  固定资产报废损失--827,649.25-
  公允价值变动损失---38,583.78-
  财务费用6,603,947.79-17,937,693.71-
  投资损失-40,205,255.59--852,610.79-
  递延所得税2,929,245.07--647,307.09-
  其中:递延所得税资产减少3,052,813.85--400,169.55-
    递延所得税负债增加-123,568.78--247,137.54-
  存货的减少-29,591,348.16--43,511,247.61-
  经营性应收项目的减少-20,584,585.3-16,288,110.96-
  经营性应付项目的增加9,001,236.34-25,996,601.96-
  其他--11,837,463.65-
  现金的期末余额64,920,914.84-85,276,030.5-
  减:现金的期初余额85,276,030.5-110,118,321.91-
  现金及现金等价物的净增加额-20,355,115.66--24,842,291.41-
公告日期2026-08-262026-04-292026-04-292025-10-24
审计意见(境内)标准无保留意见
TOP↑